Target intelligence / Profile preview

Integrin alpha chain (ITGA)

Target
ITGA
Molecular classification
Receptor, Cell adhesion molecule, Transmembrane protein
01

Overview

Integrin alpha chains are a large family of transmembrane receptor proteins that form heterodimers with beta chains to create functional integrin receptors. These receptors mediate cell-cell and cell-extracellular matrix (ECM) adhesion, and transmit signals bi-directionally across the plasma membrane, modulating key processes such as cell migration, proliferation, immune responses, and cytoskeletal arrangement. In humans, there are at least 18 known integrin alpha chains (ITGA1-ITGA11, ITGAD, ITGAE, ITGAL, ITGAM, ITGAV, ITGA2B, ITGAX), each conferring ligand-binding specificity and tissue distribution [1][2][3][4]. Integrin alpha chain family proteins are strongly implicated as drug targets, but therapeutic or pharmacological discussions must generally be conducted at the specific heterodimer (alpha-beta pair) level, as their function and disease relevance are highly context-specific [2][3].

Other names
Integrin α subunitITGA familyCD49 (for specific family members)VLA (very late antigen, for some members)LFA (for some members)GPIIb (for some members)
02

Mechanism of action

Inhibition of ligand binding (antagonism); Modulation of signaling pathways; Blockade of cell adhesion and migration

03

Biological functions

Cell-matrix adhesionCell-cell adhesionSignal transductionRegulation of cell cycleRegulation of cytoskeleton organizationImmune responseCell migration
04

Disease associations

CancerInflammationCardiovascular diseaseInfectionAutoimmune disordersOther (wide range of disorders due to the family’s diverse roles)
05

Safety considerations

Risk of immunosuppression (if therapeutically targeting certain subtypes)Bleeding tendency (if platelet integrin is targeted)Off-target effects due to broad tissue distribution
06

Biomarkers

Integrin expression levels (in specific subtypes, predictive/prognostic in cancer, inflammation, etc.)

Beyond the preview

Go deeper on Integrin alpha chain (ITGA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin alpha chain (ITGA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call